Contents
27 August 2019
Vol 12, Issue 596
Vol 12, Issue 596
Focus
- SMAC mimetics throw a molecular switch to control TH17 responses
SMAC mimetics that inhibit tumor growth can also limit autoimmunity (Rizk et al., in 27 August 2019 issue).
Research Articles
- SMAC mimetics promote NIK-dependent inhibition of CD4+ TH17 cell differentiation
By promoting noncanonical NF-κB signaling, SMAC mimetics can reprogram CD4+ T helper cell differentiation and curb autoimmunity.
- Therapeutic blockade of activin-A improves NK cell function and antitumor immunity
Activin-A inhibits NK cell effector functions and suppresses antimelanoma immunity.
Editors' Choice
- New connections: Targeting PRMTs in cancer
Drugs that block protein methyltransferases may be effective in RNA splicing–mutant cancers.
About The Cover
Online Cover This week features a Research Article that shows that the TGF-β family member activin-A inhibits the functions of natural killer (NK) cells and suppresses antimelanoma immunity in mice. The image shows a melanoma cell being targeted by a cytotoxic NK cell (red) as analyzed by scanning electron microscopy. [Image: Fernando S. F. Guimaraes/WEHI, Carolina C. Camargo/UFPR, and Simon Taplin/WEHI]
